Skip to main content

Novel Rx

    RT @RichardPAConway: Dr Marsman presents positive RCT of Rituximab in PMR. GC-free remission 48% vs 21% (p=0.049) GC<
    2 years 10 months ago
    Dr Marsman presents positive RCT of Rituximab in PMR. GC-free remission 48% vs 21% (p=0.049) GC<=5mg 100% vs 47% (p=0.005) @RheumNow #EULAR2021 Abstr#POS0343 https://t.co/tjkKTS6DMN
    RT @KDAO2011: #POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database
    88.4% live births, 10.
    2 years 10 months ago
    #POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database 88.4% live births, 10.5% preg loss, 0.8% still birth 2.4% congen malform (w/2.1% major) Preg loss⬅️Crohn's, NSAIDS, MTX Preterm labor⬅️GCs, maternal infx ⬇️birth wt⬅️RA & GCs @rheumnow #EULAR2021 https://t.co/qnNcDIz8Ge
    RT @uptoTate: Real-world data from PsABio: 🚺generally start biologics in a worse PsA state than🚹. Although treatme
    2 years 10 months ago
    Real-world data from PsABio: 🚺generally start biologics in a worse PsA state than🚹. Although treatment improvements were similar between sexes, 🚺remained in worse health at 1 yr, and stopped/switched bDMARD earlier. Abstract #OP0232 #EULAR2021 @RheumNow https://t.co/oIGu0HzisQ https://t.co/uLnYOq8ypx
    RT @AurelieRheumo: KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with
    2 years 10 months ago
    KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with 51.3% vs 26.5% in PBO group (P < .001) and ACR50 26.3% vs 9.3%. No particular safety signal. #OP0228 @Rheumnow #EULAR2021 https://t.co/HZv8qoc4sz
    RT @AurelieRheumo: Serious infections and BioDMARDs: what is the confounding factor?
    BSRBR-RA: 33,916 RA treated w/ BioD
    2 years 10 months ago
    Serious infections and BioDMARDs: what is the confounding factor? BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD
    Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021

    On day 2 of EULAR ,
    2 years 10 months ago
    Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021 On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr
    RT @TheLancetRheum: Presenting now at #EULAR2021

    #COVID19 outcomes in patients with inflammatory rheumatic and musculo
    2 years 10 months ago
    Presenting now at #EULAR2021 #COVID19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with #rituximab: a cohort study https://t.co/QTGkiMcC2d https://t.co/DJB6GooPuJ